Wall Street analysts expect Amyris Inc (NASDAQ:AMRS) to announce earnings per share (EPS) of ($0.30) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Amyris’ earnings. Amyris reported earnings per share of ($0.52) during the same quarter last year, which would suggest a positive year-over-year growth rate of 42.3%. The firm is expected to report its next quarterly earnings results on Monday, May 13th.
According to Zacks, analysts expect that Amyris will report full year earnings of ($0.19) per share for the current financial year. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Amyris.
Amyris (NASDAQ:AMRS) last issued its earnings results on Monday, March 18th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.44 by ($1.51). The company had revenue of $19.36 million for the quarter, compared to the consensus estimate of $98.52 million. During the same quarter in the prior year, the company earned $0.61 EPS. The company’s revenue was down 76.0% compared to the same quarter last year.
AMRS has been the topic of several research reports. Zacks Investment Research cut shares of Amyris from a “hold” rating to a “sell” rating in a report on Thursday, January 3rd. BidaskClub upgraded shares of Amyris from a “sell” rating to a “hold” rating in a report on Monday, January 7th. Finally, HC Wainwright set a $11.00 target price on shares of Amyris and gave the stock a “buy” rating in a report on Tuesday, February 5th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Amyris currently has an average rating of “Buy” and an average target price of $8.83.
AMRS stock traded up $0.36 on Thursday, hitting $4.41. The company had a trading volume of 40,890 shares, compared to its average volume of 4,582,411. Amyris has a 12-month low of $1.87 and a 12-month high of $9.28. The stock has a market capitalization of $309.95 million, a P/E ratio of -1.74 and a beta of 0.84.
In other Amyris news, Director L John Doerr purchased 6,732,369 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were acquired at an average price of $2.87 per share, for a total transaction of $19,321,899.03. Following the purchase, the director now directly owns 5,532 shares of the company’s stock, valued at approximately $15,876.84. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Frank Kung purchased 913,529 shares of the company’s stock in a transaction dated Monday, April 29th. The shares were acquired at an average price of $4.76 per share, for a total transaction of $4,348,398.04. Following the purchase, the director now directly owns 3,599 shares in the company, valued at $17,131.24. The disclosure for this purchase can be found here. Insiders have bought a total of 10,478,338 shares of company stock worth $38,172,390 in the last quarter. Corporate insiders own 21.80% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Amyris by 50.2% during the 4th quarter. BlackRock Inc. now owns 3,419,786 shares of the biotechnology company’s stock worth $11,421,000 after acquiring an additional 1,142,354 shares during the last quarter. Deutsche Bank AG raised its position in shares of Amyris by 2,498.9% during the 4th quarter. Deutsche Bank AG now owns 1,626,582 shares of the biotechnology company’s stock valued at $5,431,000 after purchasing an additional 1,563,994 shares during the period. Northpointe Capital LLC raised its position in shares of Amyris by 37.9% during the 4th quarter. Northpointe Capital LLC now owns 633,015 shares of the biotechnology company’s stock valued at $2,114,000 after purchasing an additional 173,853 shares during the period. WS Management Lllp bought a new stake in shares of Amyris during the 4th quarter valued at $2,101,000. Finally, JPMorgan Chase & Co. raised its position in shares of Amyris by 96.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 446,909 shares of the biotechnology company’s stock valued at $3,548,000 after purchasing an additional 219,081 shares during the period. Institutional investors and hedge funds own 35.94% of the company’s stock.
Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.
Featured Article: Municipal Bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.